文献速递消化道肿瘤与早癌

结肠癌诊断后他汀类药物使用与患者生存

Statin Use After Diagnosis of Colon Cancer and Patient Survival.
PubMed 文献 · Gastroenterology · 2017-05-13

基于荷兰PHARMO数据库网络与埃因霍温癌症登记处2002至2007年诊断的结肠癌患者数据,并对999例手术切除标本构建组织芯片,分析诊断后他汀使用与总生存的关系。他汀使用与全因死亡风险降低相关(校正RR 0.67),BMP信号通路完整者获益更大(校正RR 0.39),KRAS突变状态不影响该关联。

要点

  • 结肠癌诊断后他汀使用与全因死亡风险降低相关(校正RR 0.67,95%CI 0.51-0.87)。
  • BMP信号通路完整者他汀使用与死亡风险降低相关(校正RR 0.39,95%CI 0.22-0.68)。
  • BMP信号通路不完整者他汀使用与死亡风险无显著关联(校正RR 0.81,95%CI 0.55-1.21)。

核心结论

  • 在999例结肠癌患者分析中,他汀使用与全因或癌症死亡风险降低相关。
  • 肿瘤BMP信号通路完整者他汀获益更大,且独立于KRAS突变状态。
  • 需要随机对照试验确认这些结果。

研究设计与样本

  • 数据来自荷兰PHARMO数据库网络,链接2002至2007年埃因霍温癌症登记处诊断的结肠癌患者,死因信息来自荷兰统计局。
  • 构建999例2002至2008年手术切除结肠癌标本的组织芯片,以诊断后他汀使用状态作为时间依赖协变量分析生存。
  • 采用多变量泊松回归生存模型和Cox分析研究他汀对生存的影响,免疫组化检测SMAD4、BMPR1A、BMPR1B和BMPR2蛋白,定量PCR检测KRAS突变。
  • 主要结局指标为全因死亡率和癌症特异性死亡率。

主要发现

  • 该队列中21.0%(210/999)的患者在结肠癌诊断后被定义为他汀使用者。
  • 诊断后他汀使用与全因死亡风险降低显著相关(校正RR 0.67,95%CI 0.51-0.87,P=.003)。
  • 诊断后他汀使用与癌症死亡风险降低显著相关(校正RR 0.66,95%CI 0.49-0.89,P=.007)。
  • BMP信号通路完整者他汀使用与全因或癌症死亡风险降低相关(校正RR 0.39,95%CI 0.22-0.68,P=.001),BMP信号通路不完整者无显著关联(校正RR 0.81,95%CI 0.55-1.21,P=.106;交互作用P<.0001)。
  • KRAS突变阴性者他汀使用与死亡风险无显著关联(校正RR 0.81,95%CI 0.56-1.18,P=.273),KRAS突变阳性者无显著关联(校正RR 0.59,95%CI 0.35-1.03,P=.062;交互作用P=.90)。

关键数值与推荐

  • 肿瘤组织含SMAD4加BMPR1A、BMPR1B或BMPR2时判定为BMP信号通路完整。
  • 诊断后他汀使用与全因死亡风险降低相关:校正RR 0.67(95%CI 0.51-0.87,P=.003)。
  • 诊断后他汀使用与癌症死亡风险降低相关:校正RR 0.66(95%CI 0.49-0.89,P=.007)。
  • BMP信号通路完整者他汀使用与全因或癌症死亡风险降低相关:校正RR 0.39(95%CI 0.22-0.68,P=.001);BMP信号通路不完整者校正RR 0.81(95%CI 0.55-1.21,P=.106),交互作用P<.0001。
  • KRAS突变阴性者他汀使用与死亡风险无显著关联:校正RR 0.81(95%CI 0.56-1.18,P=.273);KRAS突变阳性者校正RR 0.59(95%CI 0.35-1.03,P=.062),交互作用P=.90。

临床怎么用

  • 作者认为他汀使用与结肠癌患者全因或癌症死亡风险降低相关。
  • 作者认为肿瘤BMP信号通路完整者他汀获益更大,且独立于KRAS突变状态。
  • 作者建议需要随机对照试验确认这些结果。

局限性

  • 需要随机对照试验确认这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Statin use has been associated with a reduced incidence of colorectal cancer and might also affect survival of patients diagnosed with colon cancer. Statins are believed to inhibit Ras signaling and may also activate the bone morphogenetic protein (BMP) signaling pathway in colorectal cancer cells. We investigated the effects of statins on overall survival of patients with a diagnosis of colon cancer, and whether their effects were associated with changes in KRAS or the BMP signaling pathways. METHODS: Data were derived from the PHARMO database network (Netherlands) and linked to patients diagnosed with colon cancer from 2002 through 2007, listed in the Eindhoven Cancer Registry. We obtained information on causes of death from statistics Netherlands. We constructed a tissue microarray of 999 colon cancer specimens from patients who underwent surgical resection from 2002 through 2008. Survival was analyzed with statin user status after diagnosis as a time-dependent covariate. Multivariable Poisson regression survival models and Cox analyses were used to study the effect of statins on survival. Tumor tissues were analyzed by immunohistochemistry for levels of SMAD4, BMPR1A, BMPR1B, and BMPR2 proteins. Tumor tissues were considered to have intact BMP signaling if they contained SMAD4 plus BMPR1A, BMPR1B, or BMPR2. DNA was isolated from tumor tissues and analyzed by quantitative polymerase chain reaction to detect mutations in KRAS. The primary outcome measures were overall mortality and cancer-specific mortality. RESULTS: In this cohort, 21.0% of the patients (210/999) were defined as statin users after diagnosis of colon cancer. Statin use after diagnosis was significantly associated with reduced risk of death from any cause (adjusted relative risk [RR], 0.67; 95% confidence interval [CI], 0.51-0.87; P = .003) and death from cancer (adjusted RR, 0.66; 95% CI, 0.49-0.89; P = .007). Statin use after diagnosis was associated with reduced risk of death from any cause or from cancer for patients whose tumors had intact BMP signaling (adjusted RR, 0.39; 95% CI, 0.22-0.68; P = .001), but not for patients whose tumors did not have BMP signaling (adjusted RR, 0.81; 95% CI, 0.55-1.21; P = .106; P < .0001 for the interaction). Statin use after diagnosis was not associated with reduced risk of death from any cause or from cancer for patients whose tumors did not contain KRAS mutations (adjusted RR, 0.81; 95% CI, 0.56-1.18; P = .273) or whose tumors did have KRAS mutations (adjusted RR, 0.59; 95% CI 0.35-1.03; P = .062; P = .90 for the interaction). CONCLUSIONS: In an analysis of 999 patients with a diagnosis of colon cancer, we associated statin with reduced risk of death from any cause or from cancer. The benefit of statin use is greater for patients whose tumors have intact BMP signaling, independent of KRAS mutation status. Randomized controlled trials are required to confirm these results.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Voorneveld PW, Reimers MS, Bastiaannet E, et al. Statin Use After Diagnosis of Colon Cancer and Patient Survival. Gastroenterology. 2017. PMID: 28512021. doi:10.1053/j.gastro.2017.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。